Zydus Pharma bags USFDA nod for Pimavanserin Capsules
Ahmedabad: Zydus Cadila's U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the US Food and Drug Administration (USFDA) to market Pimavanserin Capsules in the strength of 34 mg (USRLD: Nuplazid Capsules). Pimavanserin is an atypical antipsychotic and is indicated for the treatment of hallucinations and delusions associated with Parkinson's...
Ahmedabad: Zydus Cadila's U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the US Food and Drug Administration (USFDA) to market Pimavanserin Capsules in the strength of 34 mg (USRLD: Nuplazid Capsules).
Pimavanserin is an atypical antipsychotic and is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
The drug will be manufactured at the group's formulation manufacturing facility at SEZ Ahmedabad. The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila had earlier received tentative approval from the US Food and drug Administration (USFDA) to market Pimavanserin Tablets, 10 mg (US RLD: Nuplazid Tablets).
Read also: Zydus gets USFDA nod to Pimavanserin for Parkinson's disease-linked psychosis
Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.
The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd